Zelnate™

a novel approach to BRD management in cattle

Abstract

Bovine respiratory disease (BRD) continues to have a major economic impact on the beef and dairy industries while public perception supports reduced antimicrobial use. The objective of this research was to evaluate the efficacy of a novel non-antimicrobial, CpG motif-based DNA immunostimulant formulated in a liposome carrier (Zelnate) in the management of BRD. The program was composed of 2 phases: 1) product development and licensure, and 2) evaluation of the clinical benefit of Zelnate relative to a commercially available antimicrobial when administered in a metaphylactic fashion.